You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PTCL-NOS

Showing 1 - 25 of 241
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma Trial in Italy (Daratumumab)

Active, not recruiting
  • Refractory T-Cell Lymphoma
  • Relapsed T-Cell Lymphoma
  • Bari, Italy
  • +6 more
Aug 1, 2022

T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in Italy (Venetoclax)

Active, not recruiting
  • T-Cell Lymphoma Relapsed
  • T-Cell Lymphoma Refractory
  • Aviano, Italy
  • +12 more
Dec 20, 2022

Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)

Completed
Has Results
  • Peripheral T Cell Lymphoma
  • +18 more
  • Vancouver, British Columbia, Canada
  • +29 more
Apr 29, 2022

Peripheral T-Cell Lymphoma (PTCL NOS), Nodal Lymphomas of T Follicular Helper (TFH), Follicular T-cell Lymphoma (FTCL) Trial

Withdrawn
  • Peripheral T-Cell Lymphoma (PTCL NOS)
  • +8 more
  • (no location specified)
Mar 10, 2020

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Nanjing (CMOP+Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jun 1, 2023

T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Refractory Trial in United States (LB1901)

Active, not recruiting
  • T-Cell Lymphoma
  • +4 more
  • LB1901
  • Rochester, Minnesota
  • +3 more
Feb 15, 2022

Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma Trial in

Recruiting
  • Epstein-Barr Virus Associated Lymphoproliferative Disorder
  • +7 more
  • Nanatinostat in combination with valganciclovir
  • Birmingham, Alabama
  • +57 more
Aug 10, 2022

T-Cell Tumor, Lymphoproliferative Disorders Trial in Ann Arbor (Pacritinib)

Not yet recruiting
  • T-Cell Neoplasm
  • Lymphoproliferative Disorders
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Oct 6, 2022

Peripheral T-cell Lymphomas (PTCL) Trial in Taiwan (Lenalidomide and Gemcitabine (Dose level 11), Lenalidomide and Gemcitabine

Not yet recruiting
  • Peripheral T-cell Lymphomas (PTCL)
  • Lenalidomide and Gemcitabine (Dose level 11)
  • +3 more
  • Kaohsiung, Taiwan
  • +3 more
Nov 1, 2021

Relapsed or Refractory T Cell Lymphoma Trial in United States (ONO-4685)

Recruiting
  • Relapsed or Refractory T Cell Lymphoma
  • Birmingham, Alabama
  • +10 more
Sep 20, 2022

Peripheral T-cell Lymphoma Trial in Shanghai (PD-1 antibody+ HDAC inhibitor)

Recruiting
  • Peripheral T-cell Lymphoma
  • PD-1 antibody+ HDAC inhibitor
  • Shanghai, Shanghai, China
    Dongmei Ji
Dec 3, 2021

Relapsed or Refractory Peripheral T-Cell Lymphoma Trial in Korea, Republic of, Spain, United States (Tipifarnib)

Completed
  • Relapsed or Refractory Peripheral T-Cell Lymphoma
  • Palo Alto, California
  • +12 more
Apr 26, 2021

Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

Active, not recruiting
  • Anaplastic Large Cell Lymphoma
  • +4 more
  • Duarte, California
  • +3 more
Jul 21, 2022

Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Grade 1

Active, not recruiting
  • Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • +18 more
  • Anti-ICOS Monoclonal Antibody MEDI-570
  • +2 more
  • Duarte, California
  • +22 more
Jan 18, 2023

NSCLC, Gastric Carcinoma, Gastroesophageal Junction Carcinoma Trial in Worldwide (SEA-TGT, sasanlimab)

Recruiting
  • Non-small Cell Lung Cancer
  • +11 more
  • Birmingham, Alabama
  • +32 more
Jan 4, 2023

T-Cell Lymphoma Trial (Brentuximab vedotin, Pembrolizumab)

Not yet recruiting
  • T-Cell Lymphoma
  • (no location specified)
Jul 22, 2022

A Study of Chinese Adults With Lymphoma

Recruiting
  • Lymphoma
    • Beijing, Beijing, China
    • +18 more
    Nov 3, 2022

    Peripheral T Cell Lymphoma Trial in France (Chemotherapy + follow up, Chemotherapy + ASCT + follow up)

    Recruiting
    • Peripheral T Cell Lymphoma
    • Chemotherapy + follow up
    • Chemotherapy + ASCT + follow up
    • Amiens, France
    • +47 more
    Aug 2, 2022

    T Cell Lymphoma Trial (Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen)

    Not yet recruiting
    • T Cell Lymphoma
    • Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen
    • (no location specified)
    Mar 6, 2023

    Multiple Myeloma (MM), DLBCL, Not Otherwise Specified, Double Hit Lymphoma Trial in Spain (IDP-121)

    Recruiting
    • Multiple Myeloma (MM)
    • +5 more
    • Santander, Cantabria, Spain
    • +4 more
    Jun 19, 2023

    T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma Trial in Chicago (Fenretinide)

    Not yet recruiting
    • T-cell Lymphoma
    • +10 more
    • Chicago, Illinois
      Rush University Medical Center
    Oct 24, 2022

    PTCL Patients Who Achieved Complete Response From Frontline Treatment Trial (Selinexor)

    Not yet recruiting
    • PTCL Patients Who Achieved Complete Response From Frontline Treatment
    • (no location specified)
    Apr 18, 2023

    Alcohol Use Disorder Trial ([18F]NOS)

    Not yet recruiting
    • Alcohol Use Disorder
    • (no location specified)
    May 22, 2023

    Peripheral T-cell Lymphoma Trial in Singapore (Selinexor, ICE Chemotherapy)

    Completed
    • Peripheral T-cell Lymphoma
    • Singapore, Singapore
      National Cancer Centre Singapore
    Apr 27, 2021

    First-line Maintenance Treatment of PTCL With Chidamide.

    Recruiting
    • PTCL
    • Nanjing, Jiangsu, China
      Hematological Department, People's Hospital of Jiangsu Province
    Jul 23, 2023